🔴 Neurosense Therapeutics is trading 6.4% down today after 1-for-20 reverse stock split

Neurosense Therapeutics is trading 6.4% down at $6.58 amid a broader biotech selloff.

• The XBI is down 2.11% during the September 16, 2026 session; decline follows substantial post-split volatility after the reverse stock split became effective September 14.
• The 1-for-20 split reduced shares outstanding to approximately 1,896,902 and introduced a new CUSIP.
• Federal Reserve rate hike and higher-for-longer signals are adding pressure to risk-sensitive biotechnology stocks; no new company-specific negative announcement was identified for September 16.